Dr. DeKosky is the Aerts-Cosper Professor of Alzheimer’s Research at the University of Florida College of Medicine and the deputy director of the McKnight Brain Institute at the University of Florida. In addition, he serves as the associate director for the Florida Alzheimer’s Disease Research Center.

He is an international leader in Alzheimer’s disease, renowned for his translational biomedical research leveraging scientific findings towards development of new treatments for patients. His clinical and translational research centers on understanding the genetics, neuropsychiatric symptoms, neuroimaging, treatment and prevention of Alzheimer’s disease.

Dr. DeKosky was the founding chair of the advisory council of ISTAART, the Alzheimer Association’s International Society to Advance Alzheimer’s Disease Research and Treatment. He has led numerous advisory committees and review boards for the NIH including membership on two NIH councils. He is an ardent proponent for greater research funding for Alzheimer’s disease and has testified multiple times before U.S. Senate committees for this cause.

Dr. Sano is a professor of psychiatry and associate dean of clinical research at the Icahn School of Medicine at Mount Sinai. She also serves as the director of the Alzheimer’s Disease Research Center at the Icahn School of Medicine, a comprehensive research facility and clinical program dedicated to the study and treatment of normal aging and Alzheimer’s disease. In addition, she directs research and development at the James J. Peters Veterans Administration Medical Center in the Bronx, NY.

Dr. Sano is a neuropsychologist by training and currently conducts research into clinical trial design and the impact of pharmacological treatments on the functional abilities of individuals with cognitive impairment. During her career, Dr. Sano has been involved in numerous clinical trials for Alzheimer’s disease, Parkinson’s disease and mild cognitive impairment of aging. In addition, she has worked to develop home-based tools to assess treatments for the prevention of cognitive loss and dementia, and to assess subtle cognitive changes in the elderly, especially those with special needs.

Dr. Sano is a member of the Alzheimer’s Association Medical & Scientific Advisory Council. In addition, she was a member of the task force that developed guidelines and criteria for the diagnosis of dementia for the DSM-V and was a member of the Prevention Research Work Group for the Healthy Brain Initiative sponsored by the Center for Disease Control and Prevention and the National Institute on Aging.

Dr. Blennow is a professor of clinical neurochemistry and the head of the research team on neurochemical pathogenesis and diagnostics in the University of Gothenburg Neuroscience and Physiology Department. In addition, he is the head of the Clinical Neurochemistry Laboratory at Sahlgrenska University Hospital in Gothenburg, Sweden.

His major areas of research interest include cerebrospinal fluid (CSF) biochemical markers of the clinical diagnosis of Alzheimer’s disease and other brain disorders, including methodological aspects of cerebrospinal fluid analyses.

Dr. Blennow’s medical specialties lie in general psychiatry and clinical chemistry. In 2011 he was awarded the Henry Wisniewski Lifetime Achievement Award by the Alzheimer’s Association, and in 2016 the Söderberg Prize in Medicine for his research on Alzheimer’s disease.

Dr. Scheltens is a professor of cognitive neurology at the Vrije Universiteit Medical Center (VuMC) in Amsterdam and serves as director of the VuMC Alzheimer Center. He also holds the position of honorary professor of neurology at University College London. His main clinical and research interests are Alzheimer’s disease, vascular dementia, frontotemporal dementia, structural and functional imaging and cerebrospinal fluid (CSF) biomarkers.

Beyond his responsibilities at VuMC, Dr. Scheltens serves as vice president of Deltaplan Dementia Netherlands, a private-public partnership he founded that aims to address and manage the growing problem of dementia in The Netherlands. He is also an active member of several societies including the Dutch Society for Neurology, the International Psychogeriatric Association, the American Academy of Neurology, the Alzheimer Imaging Consortium, the ISTAART consortium and the European College of Neuropsychopharmacology. Dr. Scheltens also serves as the co-editor-in-chief of Alzheimer’s Research & Therapy and is a member of the board of the Royal Netherlands Academy of Arts and Sciences.

Dr. Ereshefsky is the founder and chief scientific officer of Follow the Molecule: CNS Consulting LLC, a consulting firm specializing in neurological drug development strategies for pharmaceutical companies and clinical investigators. In addition, he holds positions of chief scientific officer at the Collaborative Neuroscience Network and Hassman Research Institute. Dr. Ereshevsky is a founding member of The International Society for CNS Clinical Trials and Methodology, an organization devoted to promoting advances that address strategic clinical, regulatory, methodological and policy challenges that arise in the development and use of CNS therapeutic agents.

During his career, he has served as a principal investigator in over 100 clinical trials and has led applied basic science research as well as early-to-late-stage clinical research. He has been a leader in the application of translational drug development tools including neurocircuitry/biomarker-based strategies, including continuous cerebrospinal fluid (CSF) sampling, positron emission tomography (PET) and cognitive and behavioral paradigms.

Dr. Ereshevsky is a recipient of five competitive American Society of Health-System Pharmacists (ASHP) Research Foundation Fellowships in Psychiatric Pharmacotherapy for his work as a preceptor, and two United States Pharmacopeial Fellowship Awards. He serves as an ad hoc NIMH and NIAAA grants reviewer.

Dr. Schneider is a professor of psychiatry, neurology and gerontology at the Keck School of Medicine and Leonard Davis School of Gerontology of the University of Southern California. In addition, he is on the leadership of both the California Alzheimer’s Disease Research Center (ADRC) and the University of Southern California ARDC, where he is the co-director of the clinical core.

Dr. Schneider has expertise in clinical trials methods and drug development of novel metabolic and neuroregenerative compounds. His work involves outcomes assessment, approaches to modeling and clinical trials simulations.

In addition to his activities at USC, Dr. Schneider is a member of the steering committee of the Alzheimer’s Clinical Trials Consortium (ACTC), a clinical trials infrastructure launched in December 2017 and designed to accelerate and expand studies for therapies in Alzheimer’s disease and related dementias. He also serves as editor-in-chief of Alzheimer’s & Dementia: Translational Research and Clinical Interventions; senior associate editor for Current Alzheimer Research and Alzheimer’s & Dementia; and an editorial advisor for The Lancet Neurology and the Cochrane Dementia and Cognitive Improvement Group.

Dr. Harrison is an honorary professor in the department of medicine at Imperial College London and a principal consultant at Metis Cognition Ltd, an applied psychology consulting practice that advises pharmaceutical companies on the integration of cognitive testing in clinical studies.

Previously, he served as an associate professor with the Alzheimer Center at the VUmc in Amsterdam. Dr. Harrison has also held several positions in industry, most recently as head of neuropsychology at CeNeS Pharmaceuticals.

He is a member of the American Psychological Association, holds Chartered Psychologist and Associate Fellow status with the British Psychological Society, and Chartered Scientist status with the UK Science Council. He holds doctorate degrees in neuroscience and classical and ancient studies.

Dr. Zetterberg is a professor of neurochemistry at the University of Gothenburg, Sweden and at University College London, UK, as well as the head of the Sahlgrenska Academy Department of Psychiatry and Neurochemistry at the University of Gothenburg, Sweden.

With a background in molecular biology and medicine, Dr. Zetterberg has spent over a decade focusing on the development of biomarkers for Alzheimer’s disease and other brain disorders. His research involves evaluation of biomarkers in cell and animal models, as well as in longitudinal studies of patients and healthy individuals.

He has published more than 900 scientific articles and has received the Erik K. Fernström prize for young scientists and the Inga Sandeborg prize for research on Alzheimer’s disease.